SCHEMBL13865857

SCHEMBL13865857

Cc1cccc(-c2nc3c(C)cccc3nc2Cl)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.49
▸ MAPT P10636 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ ATM Q13315 1/20 0.36
▸ MGAM O43451 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ SI P14410 2/20 0.35
▸ MGAM2 Q2M2H8 2/20 0.35
▸ MBNL1 Q9NR56 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ RXFP1 Q9HBX9 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ ACHE P22303 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13865843 0.84 RAB9A (0.51) RAB9AMAPTMAPK1ATMMGAM
SCHEMBL14842553 0.76 KDM4E (0.62) RAB9AMAPTMAPK1L3MBTL1GAA
SCHEMBL2423180 0.76 TDP1 (0.52) RAB9AMAPTMAPK1L3MBTL1MGAM
SCHEMBL31399980 0.76 TDP1 (0.52) RAB9AMAPTMAPK1L3MBTL1MGAM
SCHEMBL14764520 0.73 MAPT (0.44) RAB9AMAPTMAPK1L3MBTL1MGAM
SCHEMBL16934069 0.72 ACHE (0.46) RAB9AATMMGAMGAASI
SCHEMBL6351978 0.72 L3MBTL1 (0.58) RAB9AMAPTMAPK1L3MBTL1MBNL1
SCHEMBL20475325 0.70 RAB9A (0.53) RAB9AMAPTMAPK1GAAALDH1A1
SCHEMBL31643056 0.70 RAB9A (0.53) RAB9AMAPTMAPK1GAAALDH1A1
SCHEMBL14764415 0.70 MAPT (0.44) RAB9AMAPTMAPK1L3MBTL1MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137597-A1 Novel quinoxalinone derivatives MSD K.K. (JP) 2009-05-28 — — US disclosed
US-7388010-B2 Quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137597-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB7 RAB9A 1059/4885MAPT 4476/4885MAPK1 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback